Spots Global Cancer Trial Database for Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Official Title: A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Study ID: NCT03397394
Interventions
Study Description
Brief Summary: The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pinnacle Oncology, Honor Health, Scottsdale, Arizona, United States
University of California San Diego (UCSD), Moores Cancer Center, La Jolla, California, United States
University of California, Los Angeles (UCLA), Los Angeles, California, United States
Universityof California, Irvine, Orange, California, United States
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States
Stanford University School of Medicine, Stanford, California, United States
Hartford Health Care Cancer Institute, Hartford, Connecticut, United States
Eastern Connecticut Hematology & Oncology Associates (ECHO), Norwich, Connecticut, United States
Medstar Georgetown University Medical Center, Washington, District of Columbia, United States
Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, United States
Northwestern University, Chicago, Chicago, Illinois, United States
Indiana University - Melvin and Bren Simon Cancer Center (IUSCC), Indianapolis, Indiana, United States
The University of Iowa and Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Norton Cancer Center, Louisville, Kentucky, United States
Ochsner Cancer Institute, New Orleans, Louisiana, United States
University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
Minnesota Oncology Hematology P.A. (USO - US Oncology), Minneapolis, Minnesota, United States
Comprehensive Cancer Centers of Nevada (CCCN), Las Vegas, Nevada, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
University of New Mexico UNM Cancer Research and Treatment Center, Albuquerque, New Mexico, United States
New York Oncology Hematology, P.C. (USO - US Oncology), Albany, New York, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
New York - Presbyterian Hospital-Weill Cornell Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Duke University, Duke Cancer Institute, Durham, North Carolina, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Northwest Cancer Specialists P.C. (USO - US Oncology), Portland, Oregon, United States
Providence Portland Medical Center, Portland, Oregon, United States
Oregon Health and Science University, Portland, Oregon, United States
Lehigh Valley Health Network, Allentown, Pennsylvania, United States
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
Atlantic Urology Clinics, Myrtle Beach, South Carolina, United States
University Oncology & Hematology, Chattanooga, Tennessee, United States
Urology Associates, Nashville, Tennessee, United States
Texas Oncology PA (USO - US Oncology), Dallas, Texas, United States
University of Texas, UT Health Science Center, Houston, Texas, United States
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
University of Virginia, Emily Couric Clinical Center, Charlottesville, Virginia, United States
University of Washington / Seattle Cancer Care Alliance, Seattle, Washington, United States
Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Centre de Lutte Contre le Cancer (CLCC) - Universite de Lyon - Centre Leon-Berard, Lyon, , France
Hopital Saint-Louis, Paris, , France
Centre de Lutte Contre le Cancer - Institut de Cancerologie de l'Ouest - Rene Gauducheau, Saint-Herblain, , France
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, , France
Institut Gustave Roussy, Villejuif, , France
Urologische und Kinderurologische Universitätsklinik im Malteser, Erlangen, , Germany
Universitatsklinikum Munster / Urologie und Kinderurologie, Münster, , Germany
Studienpraxis Urologie, Nurtingen, , Germany
Fondazionerca sul Cancro ONLUS - Istituto di Candiolo IRCCS, Candiolo, , Italy
IRCCS Ospedale San Raffaele - Medical Oncology Dept, Milano, , Italy
Fondazione IRCCS Istituto Nazionale Tumori, Milano, , Italy
Azienda Ospedaliera Universitaria Federico II Oncologia Medica, Naples, , Italy
Universidad de Navarra - Clinica Universitaria de Navarra, Pamplona, Navarre, Spain
Hospital del Mar, Barcelona, , Spain
Hospital Santa Creu i Sant Pau, Barcelona, , Spain
Hospital Universitari Vall d'Hebron de Barcelona, Barcelona, , Spain
Hospital General Universitario Gregorio Maranon, Madrid, , Spain
Clinica Universitaria de Navarra Madrid, Madrid, , Spain
MD Anderson Cancer Center, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Clínico Universitario de Santiago de Compostela, Santiago De Compostela, , Spain
Sarah Cannon Research Institute - United Kingdom - London Office, London, , United Kingdom
Guy's & St. Thomas' Hospital (London Oncology Clinic), London, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
